Profile
PPBT VRTX VRNA REGN ALNY ARGX
Company Name Purple Biotech Ltd. Vertex Pharmaceuticals Incorporated Verona Pharma plc Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $10.33K $108.04B $72.68B $67.32B $58.93B $50.54B
Employees 0.01K 6.10K 0.21K 15.16K 2.23K 1.60K
CEO Michael Schickler Reshma Kewalramani FASN, David S. Zaccardelli Leonard S. Schleifer Yvonne L. Greenstreet Timothy Van Hauwermeiren EMBA,
Ratings
PPBT VRTX VRNA REGN ALNY ARGX
Quant Rating Score 2 3 1 4 2 4
Quant Rating Sell Neutral Strong Sell Buy Sell Buy
Trading
PPBT VRTX VRNA REGN ALNY ARGX
Last Close $0.861 $426 $106.91 $642.25 $434.07 $826.28
High 52 $8.4 $516.74 $106.91 $829.43 $491.09 $849.46
Low 52 $0.56 $366.54 $35.37 $482.92 $224.58 $532.27
Price vs. 52 Week High -89.75 % -17.56 % 0 % -22.57 % -11.61 % -2.73 %
Price vs. 52 Week Low 53.75 % 16.22 % 202.26 % 32.99 % 93.28 % 55.24 %
Total Return
PPBT VRTX VRNA REGN ALNY ARGX
1 Month Return 45 % 5.63 % 0.11 % 7.04 % -4.88 % 3.29 %
3 Month Return -61.04 % -9.8 % 1.37 % 12.37 % 3.45 % 19.7 %
6 Month Return -62.89 % -15 % 47 % 6.05 % 67.34 % 27.18 %
9 Month Return -72.92 % -11.67 % 78.36 % -7.86 % 60.17 % 26.87 %
YTD Return -81.64 % 5.79 % 130.21 % -9.84 % 84.47 % 34.35 %
1 Year Return -71.01 % -9.9 % 180.24 % -22.51 % 60.8 % 40.36 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
PPBT VRTX VRNA REGN ALNY ARGX
Dividend Yield Percentage (TTM) - - - 0.41 % - -
Dividend Paid and Capex Coverage Ration (TTM) - 11.09 % -147.93 % 4.25 % 5.97 % 65.28 %
Dividend Per Share (TTM) - - - 2.64 % - -
Payout Ratio (TTM) - - - 6.06 % - -
Growth
PPBT VRTX VRNA REGN ALNY ARGX
Asset Growth -16.4 % 53.91 %
Gross Profit Growth -94797.96 % 5941.02 %
Revenue Growth -100 % -
Revenue 3 Year - -23.33 %
Revenue 5 Year -100 % 290254.46 %
Revenue 10 Year - -
EBIT Growth 63.67 % -162.64 %
Net Income Growth -36318.51 % -218.96 %
Net Income 3 Yeari Growth Per Share 86.44 % -126.38 %
Net Income 5 Yeari Growth Per Share 95.36 % 33.14 %
Net Income 10 Yeari Growth Per Share 99.94 % -7.28 %
Operating Income Growth 50.59 % -127.96 %
Operating Cash Flow Growth (CFG) 27.89 % -143.33 %
Operating 3 Year CFG 67.19 % -166.57 %
Operating 5 Year CFG 90.36 % 55.51 %
Operating 10 Year CFG 99.86 % 41.1 %
EPS Growth -2579.26 % -200 %
EPS Diluted Growth -2579.26 % -215.05 %
Book Value Per Share -54.32 % -24.01 %
Share Holder 3 Year Equity Growth Per Share -82.55 % 0.26 %
Share Holder 5 Year Equity Growth Per Share -88.19 % -25.62 %
Share Holder 10 Year Equity Growth Per Share -98.16 % -72.3 %
Dividend Per Share Growth - -
Dividend 3 Year Growth Per Share - -
Dividend 5 Year Growth Per Share - -
Dividend 10 Year Growth Per Share - -
Debt Growth -47.86 % 139.05 %
Free Cash Flow Growth 27.91 % -144.48 %
Updated On 31 Dec 2024 31 Dec 2024
Profitability
PPBT VRTX VRNA REGN ALNY ARGX
Gross Profit Margin TTM - 86.11 % 95.15 % 85.39 % 51.22 % 65.82 %
Return on Assets TTM -7.59 % 15.13 % -14.17 % 11.4 % 0.9 % 15.06 %
Return on Equity TTM -8.23 % 22.14 % -38.66 % 15.31 % 26.13 % 18.96 %
Return on Capital Employed TTM -17.99 % 19.72 % -10.74 % 10.32 % 8.03 % 5.04 %
Net Income Per EBT TTM 99.35 % 83.16 % 111.3 % 88.98 % -136.38 % 237.3 %
EBT Per Ebit TTM 45.38 % 111.48 % 130.22 % 139.5 % -12.07 % 147.38 %
EBIT Per Revenue TTM - 34.36 % -25.27 % 25.89 % 8.25 % 13.47 %
Cash Flow To Debt Ratio TTM -8573.79 % 251.83 % -29.66 % 187.43 % 20.32 % 932.29 %
Receivables Turnover TTM - 6.03 2.55 2.51 3.33 1.91
Payables Turnover TTM 0.09 3.59 3.13 2.3 2.69 0.9
Inventory Turnover TTM - 1.06 1.25 0.64 4.2 2.26
Fixed Asset Turnover TTM - 431.08 % 8642.22 % 284.82 % 463.12 % 5009.77 %
Asset Turnover TTM - 47.51 % 38.7 % 35.47 % 66.16 % 31.97 %
Operating Cash Flow Per Share TTM -0.02 14.98 -0.85 48.94 2.02 5.67
Free Cash Flow Per Share TTM -0.02 13.63 -0.85 40.09 1.68 5.58
Cash Per Share TTM 1.08 % 2486.48 % 511.44 % 8148.65 % 2072.79 % 5536.58 %
Operating Cash Flow Sales Ratio TTM - 33.68 % -32.7 % 35.59 % 8.28 % 17.54 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.02 % 90.99 % 100.75 % 81.92 % 83.26 % 98.47 %
Cash Flow Coverage Ratios TTM -8573.79 % 251.83 % -29.66 % 187.43 % 20.32 % 932.29 %
Price To Free Cash Flows Ratio TTM -0.28 30.87 -995.27 16.2 266.2 126.54
Price To Operating Cash Flows Ratio TTM -0.29 28.12 -126.33 13.32 222.27 144.53
Price Cash Flow Ratio TTM -0.29 28.12 -126.33 13.32 222.27 144.53
Income Statement (TTM)
PPBT VRTX VRNA REGN ALNY ARGX
Revenue $0B $11.02B $0.03B $14.2B $2.25B $2.19B
Gross Profit $-0B $9.49B $0.03B $12.23B $1.92B $1.96B
Gross Profit Ratio 0% 86.11% 93.89% 86.13% 85.62% 89.62%
EBITDA $-0.01B $0.49B $-0.12B $5.32B $-0.18B $0.11B
Net Income $-0.01B $-0.54B $-0.14B $4.41B $-0.28B $0.83B
EPS Diluted -4.42 -2.08 -1.73 38.34 -2.18 12.78
Balance Sheet (MRQ)
PPBT VRTX VRNA REGN ALNY ARGX
Long Term Debt $0B $1.66B $0.12B $2.7B $2.59B $0.03B
Total Liabilities $0B $6.12B $0.27B $8.41B $4.23B $0.7B
Total Equity $0.03B $16.41B $0.2B $29.35B $0.07B $5.5B
Total Investments $0B $6.65B $0.02B $15.42B $1.8B $1.93B
Total Debt $0B $1.75B $0.12B $2.7B $2.74B $0.04B
Total Assets $0.04B $22.53B $0.47B $37.76B $4.3B $6.2B
Cash Flow Statement (TTM)
PPBT VRTX VRNA REGN ALNY ARGX
Net Income $-0.01B $-0.54B $-0.17B $4.41B $-0.28B $0.83B
Inventory $0B $-0.52B $-0.01B $-0.62B $0.01B $-0.1B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $-0.12B $4.42B $-0.01B $-0.08B
Capital Expenditure $0B $-0.3B $-0B $-0.76B $-0.03B $-0.07B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 33.25
AARD Aardvark Therapeutics, Inc. Common Stock 9.865
ABCL AbCellera Biologics Inc. 4.865
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.57
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.955
ABPWW 0.0137
ABSI Absci Corporation 3.955
ABUS Arbutus Biopharma Corporation 4.495
ABVC ABVC BioPharma, Inc. 2.8374
ABVX Abivax SA American Depositary Shares 98.625
ACAD ACADIA Pharmaceuticals Inc. 21.83
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.6826
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.795
ACIU AC Immune SA 3.305
Unlock